genosmart DX All Cancer SolidDNA-405
Our biggest and most comrehensive gene panel
Useful for
The DB-DNA-PanCancer-Solid405 Panel is a targeted resequencing assay for the biomarker analysis of 405 genes with known relevance to solid tumours. Our panel provides a better understanding of tumour behaviour and its likelihood to respond to a treatment thus enabling tailored medicine for the patient and frequently leading to a better outcome or reduced adverse effects.
Speciment type requirements
500 ng (min. 10 ng/ul) purified DNA from FFPE or frozen tumour samples
Required information
DNA concentration and tumour ratio
Clinical interpretation
Targeted cancer therapies are defined as antibody or small molecule drugs that block the growth and spread of cancer by interfering with specific cell molecules involved in tumour growth and progression. Multiple targeted therapies have been approved for treatment of specific cancers. Molecular genetic profiling is often needed to identify targets amenable to targeted therapies and to minimize treatment costs and therapy-associated risks. The results of this test can be useful for assessing prognosis and guiding treatment of individuals with tumours. These data can also be used to help determine clinical trial eligibility for patients with alterations in genes not amenable to currently approved targeted therapies.
Cautions
This test cannot differentiate between somatic and germline alterations. Additional testing may be necessary to clarify the significance of results if there is a potential hereditary risk. DNA variants of uncertain significance may be identified. A negative (wild-type) result does not rule out the presence of a mutation or rearrangement (fusion) that may be present but below the limits of detection of this assay. Rare polymorphisms may be present that could lead to false-negative or false-positive results. Test results should be interpreted in the context of clinical findings, tumour sampling, and other laboratory data. If results obtained do not match other clinical or laboratory findings, please contact the laboratory for updated interpretation. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.
NGS
If you have prepared your own libraries, but you do not want to invest to a next generation sequencer or you want short TAT with low cost, use our sequencing capacity
Bioinformatics
If you prepared and sequenced your samples, but want to have an accurate and in depth, fully annotated analysis with help in therapeutic decisions use our bioinformatics service
